Contact us 24/7

Pradaxa

Reports of Fatal Bleeding in Pradaxa Patients

Pradaxa (dabigatran) is a blood thinning (anticoagulant) drug approved to prevent blood clotting and strokes in patients with atrial fibrillation (abnormal heart rhythm). Since its approval in 2010, Pradaxa manufacturer Boehringer Ingelheim has received hundreds of reports of fatal bleeding in patients taking the drug, including several cases ending in death. The Food and Drug Administration (FDA) is currently investigating these reports.

PRADAXA SIDE-EFFECTS

  • Abnormal bleeding
  • Blood in vomit, urine, or stool
  • Ulcers (digestive tract)
  • Indigestion/heartburn
  • Abdominal paint or discomfort
  • Cerebral hemorrhaging
  • Life-threatening internal bleeding

PRADAXA STUDY

A recent study, conducted by doctors at the Cleveland Clinic and published in the Jan. 9 issue of Archives of Internal Medicine, found that Pradaxa boosted the risk of a heart attack and acute coronary syndrome by 33% when compared to alternate therapies. The study involved more than 30,000 people taking either Pradaxa, warfarin, enoxaparin, or a placebo..

HAVE YOU BEEN INJURED?

If you’ve been injured, we can help. Contact us